Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Argenx Se ( (ARGX) ) has shared an announcement.
Argenx SE has announced its strategic priorities for 2025, aiming to transition to sustainable profitability while continuing to invest in innovation. The company reported $2.2 billion in preliminary full-year 2024 global product net sales and plans to expand its global reach with VYVGART and other pipeline products. Key initiatives include the launch of VYVGART SC as a pre-filled syringe, ongoing registrational studies, and advancing several new molecules. These efforts are part of Argenx’s long-term ‘Vision 2030’ to transform autoimmune disease treatment, with goals of treating 50,000 patients globally and securing 10 labeled indications across its medicines.
More about Argenx Se
Argenx SE is a global immunology company focused on developing treatments for severe autoimmune diseases. It is known for its innovative approach in the immunology sector, particularly through its products like VYVGART, which is an FcRn blocker approved for multiple indications. Argenx is committed to advancing its pipeline of precision therapies and expanding its global reach.
YTD Price Performance: 5.82%
Average Trading Volume: 266,003
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $39.87B
See more insights into ARGX stock on TipRanks’ Stock Analysis page.
